Semaglutide: The FDA-Approved Exception
Unlike most compounds covered on this site, semaglutide has a growing list of genuine FDA approvals — and 2026 alone brought a real milestone: the first oral GLP-1 pill approved for weight loss.
Approval Timeline
Ozempic Approved for Type 2 Diabetes
Semaglutide, a GLP-1 receptor agonist, received its first FDA approval as Ozempic in December 2017 — an injectable to improve glycemic control in adults with type 2 diabetes.
Rybelsus Becomes the First Oral GLP-1
Rybelsus launched as the first oral GLP-1 approved for type 2 diabetes — a genuinely different product from the newer Wegovy pill, worth distinguishing clearly (see below).
Wegovy Approved for Chronic Weight Management
Wegovy — the same molecule, a higher dose, different branding — was approved in June 2021 for adults with obesity or overweight plus a weight-related condition.
Cardiovascular and Kidney Indications Added
Based on the SELECT trial, Wegovy gained an indication to reduce major adverse cardiovascular events in adults with established cardiovascular disease. Separately, based on the FLOW trial, Ozempic gained an indication to reduce kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
MASH Indication Added — Under Accelerated Approval
Wegovy was approved for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) — a liver condition. This indication is under accelerated approval, meaning continued approval may depend on confirmatory trial results.
The Wegovy Pill: First Oral GLP-1 for Weight Loss
On December 22, 2025, the FDA approved the Wegovy pill (25 mg once-daily oral semaglutide) — the first oral GLP-1 approved specifically for weight management, launching in the US in early 2026.
Rybelsus vs. the New Wegovy Pill — Don’t Confuse Them
Two oral semaglutide pills now exist, and they are not interchangeable.
Approved for type 2 diabetes only. Lower doses (up to 14 mg). Produces modest weight loss (roughly 3–5%) — not approved or typically prescribed for weight loss.
Approved specifically for weight management. Higher dose (25 mg). Produces weight loss comparable to injectable Wegovy.
Semaglutide’s FDA label carries a boxed warning for thyroid C-cell tumors observed in animal studies, and it’s contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The most common adverse reactions across trials are gastrointestinal — nausea, vomiting, and diarrhea.
Compounded Semaglutide Is a Different Story Now
Both Ozempic (from August 2022) and Wegovy (from March 2022) spent time on the FDA’s official drug shortage list, which temporarily allowed compounding pharmacies to prepare semaglutide. The FDA has since declared those shortages resolved — meaning the legal basis for most compounded semaglutide has ended, the same pattern we’ve covered for tirzepatide. Products still marketed as compounded or “research” semaglutide fall outside that now-closed exemption.
The takeaway: semaglutide has the deepest, broadest FDA approval history of any compound on this site — diabetes, weight management, cardiovascular risk, kidney disease, and now MASH, across both injectable and (as of 2026) oral forms. The thing to get right isn’t whether it’s approved — it clearly is — it’s making sure you’re getting the specific approved product and indication that actually matches what you’re being treated for, from a licensed pharmacy.
For a related FDA-approved peptide, see our guide on Tirzepatide.
References
- U.S. Food and Drug Administration (2017) Ozempic (semaglutide) Prescribing Information, initial approval December 2017.
- U.S. Food and Drug Administration (2021) Wegovy (semaglutide) FDA Approval, 4 June 2021.
- U.S. Food and Drug Administration (2025) Wegovy MASH indication approval, accelerated approval pathway.
- Novo Nordisk (2025) ‘FDA Approves Novo Nordisk’s Wegovy® Pill, the First and Only Oral GLP-1 for Weight Loss in Adults’, press release, 22 December 2025.
- Applied Clinical Trials (2026) ‘FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results’.
- U.S. Food and Drug Administration (2026) Declaratory Order: Resolution of Shortages of Semaglutide Injection Products.